10x Genomics Unveils Chromium Xo: A Low-Cost Instrument to Expand Access to High-Performance Single Cell Research
10x Genomics has launched Chromium Xo, a new low-cost single cell instrument priced at $25,000, aimed at expanding access to high-performance single cell research. This addition to the Chromium fleet is designed for researchers with budgets, offering high-quality data and superior reproducibility.
Key features of Chromium Xo include:
- Compatibility with the GEM-X 3' assay, providing up to 80% cell capture and 40% higher gene sensitivity
- Potential for 50% savings on sequencing costs compared to non-10x methods
- Automation for partitioning hundreds of thousands of cells in minutes
- Intuitive push-button interface for efficient cell processing
The instrument aims to democratize single cell analysis and drive towards the goal of enabling high-performance analysis for $100 per sample.
10x Genomics ha lanciato Chromium Xo, un nuovo strumento per cellule singole a basso costo, con un prezzo di 25.000 dollari, mirato ad ampliare l'accesso alla ricerca su cellule singole ad alte prestazioni. Questa aggiunta alla flotta Chromium è progettata per ricercatori con budget limitato, offrendo dati di alta qualità e superiore riproducibilità.
Le principali caratteristiche di Chromium Xo includono:
- Compatibilità con il test GEM-X 3', che fornisce fino al 80% di cattura cellulare e 40% di sensibilità genica in più
- Possibilità di risparmiare il 50% sui costi di sequenziamento rispetto ai metodi non 10x
- Automazione per il partizionamento di centinaia di migliaia di cellule in pochi minuti
- Interfaccia intuitiva con un pulsante per un'elaborazione efficiente delle cellule
Lo strumento ha l'obiettivo di democratizzare l'analisi delle cellule singole e di portare verso l'obiettivo di abilitare un'analisi ad alte prestazioni per 100 dollari per campione.
10x Genomics ha lanzado Chromium Xo, un nuevo instrumento de bajo costo para células individuales con un precio de $25,000, diseñado para ampliar el acceso a la investigación de células individuales de alto rendimiento. Esta adición a la flota de Chromium está dirigida a investigadores con presupuestos ajustados, ofreciendo datos de alta calidad y superior reproducibilidad.
Las características clave de Chromium Xo incluyen:
- Compatibilidad con el ensayo GEM-X 3', proporcionando hasta un 80% de captura celular y 40% más de sensibilidad genética
- Potencial de ahorros del 50% en costos de secuenciación en comparación con los métodos no 10x
- Automatización para particionar cientos de miles de células en minutos
- Interfaz intuitiva de un solo botón para un procesamiento eficiente de las células
El instrumento tiene como objetivo democratizar el análisis de células individuales y avanzar hacia la meta de permitir un análisis de alto rendimiento por $100 por muestra.
10x Genomics는 Chromium Xo라는 새로운 저비용 단일 세포 기기를 출시했습니다. 이 기기는 $25,000의 가격으로 제공되며, 고성능 단일 세포 연구에 대한 접근성을 확대하는 데 목적을 두고 있습니다. Chromium 제품군에 새롭게 추가된 이 기기는 예산이 제한된 연구자들을 위해 설계되었으며, 고품질 데이터와 우수한 재현성을 제공합니다.
Chromium Xo의 주요 기능은 다음과 같습니다:
- 최대 80%의 세포 포획과 40% 더 높은 유전자 감도를 제공하는 GEM-X 3' 분석과의 호환성
- 비 10x 방법에 비해 50%의 시퀀싱 비용 절감 가능성
- 몇 분 안에 수십만 개의 세포를 분리할 수 있는 자동화
- 효율적인 세포 처리를 위한 직관적인 버튼 인터페이스
이 기기는 단일 세포 분석의 민주화를 목표로 하고 있으며, 샘플당 $100의 가격으로 고성능 분석을 가능하게 하는 목표를 향해 나아가고 있습니다.
10x Genomics a lancé Chromium Xo, un nouvel instrument de cellule unique à bas coût, au prix de 25 000 $, visant à élargir l'accès à la recherche de cellule unique à haute performance. Cet ajout à la flotte Chromium est conçu pour les chercheurs avec des budgets, offrant des données de haute qualité et une reproductibilité supérieure.
Les principales caractéristiques de Chromium Xo comprennent :
- Compatibilité avec l'assai GEM-X 3', offrant jusqu'à 80 % de capture cellulaire et 40 % de sensibilité génique en plus
- Potentiel d'économies de 50 % sur les coûts de séquençage par rapport aux méthodes non 10x
- Automatisation pour le partitionnement de centaines de milliers de cellules en quelques minutes
- Interface intuitive à bouton-poussoir pour un traitement cellulaire efficace
L'instrument vise à démocratiser l'analyse des cellules uniques et à progresser vers l'objectif de permettre une analyse à haute performance pour 100 $ par échantillon.
10x Genomics hat Chromium Xo eingeführt, ein neues, kostengünstiges Einzelzellinstrument, das auf 25.000 $ ausgelegt ist und darauf abzielt, den Zugang zu hochleistungsfähiger Einzelzellforschung zu erweitern. Diese Erweiterung der Chromium-Flotte richtet sich an Forscher mit begrenzten Budgets und bietet hochwertige Daten und überlegene Reproduzierbarkeit.
Zu den Hauptmerkmalen von Chromium Xo gehören:
- Kompatibilität mit dem GEM-X 3'-Assay, das bis zu 80% Zellfang und 40% höhere Genempfindlichkeit bietet
- Potenzielle 50% Einsparungen bei den Sequenzierungskosten im Vergleich zu nicht 10x-Methoden
- Automatisierung zur Partitionierung von Hunderttausenden von Zellen in Minuten
- Intuitive Schnittstelle mit Druckknopf für eine effiziente Zellbearbeitung
Das Instrument zielt darauf ab, die Einzelzellanalyse zu demokratisieren und auf das Ziel hinzuarbeiten, die hochleistungsfähige Analyse für 100 $ pro Probe zu ermöglichen.
- Launch of Chromium Xo, a low-cost single cell instrument priced at $25,000
- GEM-X 3' assay offers up to 80% cell capture and 40% higher gene sensitivity
- Potential for 50% savings on sequencing costs compared to non-10x methods
- Automation and intuitive interface improve efficiency and reproducibility
- Path for researchers to upgrade to Chromium X for access to full single cell portfolio
- None.
The launch of Chromium Xo represents a significant market expansion strategy for 10x Genomics. By offering a
The emphasis on cost-efficiency, including
While the
Investors should focus on:
- Adoption rates and their effect on overall instrument sales mix
- Changes in consumables revenue per instrument
- Upgrade rates to higher-end models
The introduction of Chromium Xo could be a game-changer in the single cell analysis market. By significantly lowering the entry barrier, 10x Genomics is poised to capture a larger share of the academic and small biotech segments, which have been price-sensitive. This move may force competitors to respond, potentially triggering a price war in the industry.
The focus on ease of use and automation addresses key pain points in manual workflows, which could accelerate market adoption. The promise of
"Chromium Xo is the latest in a series of 10x innovations intended to democratize single cell analysis because we never want researchers to have to settle for anything less than the best," said Ben Hindson, Chief Scientific Officer and Co-founder. "With Chromium Xo, we're not just lowering the cost barrier; we're empowering more researchers to achieve high-quality, repeatable results necessary for meaningful scientific breakthroughs."
Chromium Xo is 10x Genomics' most affordable single cell instrument, delivering the high-quality data, superior reproducibility and ease of use that the company's instrument-powered workflows are known for, at a
Chromium Xo is specifically designed to run 10x Genomics' industry-leading GEM-X 3' assay, which provides up to
In addition, there is a path for researchers to seamlessly upgrade to Chromium X to access the full breadth of the company's single cell portfolio, including assays for FFPE samples and immune profiling.
With features like automation to partition hundreds of thousands of cells in minutes and an intuitive push-button interface for efficient cell processing, Chromium instruments remove many of the challenges and inconsistencies of manual, instrument-less workflows. The instrument-powered Chromium platform enables high data quality and twice the sample recovery as manual methods. In addition, Chromium instruments streamline the workflow, improve scalability and enable superior reproducibility, resulting in less hands-on time, lower labor and experimental costs and faster time to results compared to alternative single cell workflows.
Added Hindson, "Our ultimate goal is to enable high-performance single cell analysis for
Chromium Xo is now shipping globally.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter).
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which fall under the "safe harbor" provisions of those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "see," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding 10x Genomics, Inc.'s ("10x Genomics") and others' product launches, performance, configuration, costs, capabilities, requirements, workflows, adoption and pipeline. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors. Other risks and uncertainties that could affect 10x Genomics' financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents 10x Genomics files with the Securities and Exchange Commission (the "SEC") from time to time. Although 10x Genomics believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to 10x Genomics as of the date hereof, and 10x Genomics disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing 10x Genomics' views as of any date subsequent to the date of this press release.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-unveils-chromium-xo-a-low-cost-instrument-to-expand-access-to-high-performance-single-cell-research-302237175.html
SOURCE 10x Genomics, Inc.
FAQ
What is the price of the new Chromium Xo instrument from 10x Genomics (TXG)?
What are the key features of the Chromium Xo instrument from 10x Genomics (TXG)?
How does the Chromium Xo from 10x Genomics (TXG) compare to alternative single cell workflows?
What is 10x Genomics' (TXG) goal for the cost of high-performance single cell analysis?
